BB Biotech AG provides investment services for biotechnology sector. The company is headquartered in Schaffhausen, Schaffhausen and currently employs 86 full-time employees. The company went IPO on 2006-11-08. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
How did BBAGF's recent EPS compare to expectations?
The most recent EPS for BB Biotech AG is $, expectations of $.
How did BB Biotech AG BBAGF's revenue perform in the last quarter?
BB Biotech AG revenue for the last quarter is $
What is the revenue estimate for BB Biotech AG?
According to of Wall street analyst, the revenue estimate of BB Biotech AG range from $ to $
What's the earning quality score for BB Biotech AG?
BB Biotech AG has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does BB Biotech AG report earnings?
BB Biotech AG next earnings report is expected in 2026-05-21
What are BB Biotech AG's expected earnings?
BB Biotech AG expected earnings is $, according to wall-street analysts.